Home | Careers | Contact Us | Sitemap 
   Other Country Sites Search
Products
Prescription Dermatology Products

Consumer Dermatology Products

ADR's

Consumer Product Safety Certifications

Generic FAQs
 



Home 
Brands


Branded Pharmaceutical Business


Brands
Ranbaxy Laboratories Inc. (RLI) is committed to developing
a distinguished branded pharmaceutical business. The
foundation for establishing the branded business rests
on three strategic pillars:

Licensing/acquisitions
In-house product development
Marketing alliances.

RLI is actively looking to acquire more products to augment product offerings to its customers.

An important factor of the growth of Ranbaxy’s branded business is product development expertise. In addition to research on New Chemical Entities (NCE), Ranbaxy has highly developed capabilities in Novel Drug Delivery Systems (NDDS) that offer new and improved formulations to currently available chemical entities. For example, Ranbaxy developed a once-daily formulation of the anti-infective Cipro® (ciprofloxacin) which it has licensed to Bayer, the original marketer of the drug.

Ranbaxy hopes to take advantage of its product development expertise by launching its own proprietary brands, which are currently at various stages of development.

Having a well defined branded product portfolio, the company is actively looking for marketing partners with complimentary skills and needs.

RLI's branded prescription division in the U.S. market will expand and grow through Ranbaxy’s R&D efforts, continued exploration of NDDS, licensing activities and mergers and acquisitions. RLI's commitment to invest significantly in R&D will translate into the development of innovative, brand name products with a wide range of therapeutic uses.